

A New Sparteine Surrogate for Asymmetric Deprotonation of *N*-Boc Pyrrolidine


Darren Stead,[†] Peter O'Brien,^{*,†} and Adam Sanderson[‡]

Department of Chemistry, University of York, Heslington, York YO10 5DD, United Kingdom, and Eli Lilly and Co. Ltd, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, United Kingdom

paob1@york.ac.uk

Received January 21, 2008

ABSTRACT



The *s*-BuLi complex of a cyclohexane-derived diamine is as efficient as *s*-BuLi/(–)-sparteine for the asymmetric deprotonation of *N*-Boc pyrrolidine. This is the first example of high enantioselectivity using a non-sparteine-like diamine in such reactions. The (*S,S*)-diamine is a useful (+)-sparteine surrogate and was utilized in short syntheses of (–)-indolizidine 167B and an intermediate for the synthesis of the CCK antagonist (+)-RP 66803.

Seminal work from the groups of Hoppe¹ and Beak² has highlighted the importance and effectiveness of the natural alkaloid (–)-sparteine as a ligand for *s*-butyllithium in asymmetric deprotonation processes.³ In earlier work, we addressed the limitation of accessing products with (+)-sparteine-derived stereochemistry by introducing a readily available (+)-sparteine surrogate (+)-**1** (Figure 1).^{4,5} Diamine (+)-**1** is as efficient as (–)-sparteine in the *s*-BuLi-mediated asymmetric deprotonation of *N*-Boc pyrrolidine and *O*-alkyl carbamates but, importantly, delivers products with opposite enantioselectivity. Diamine (+)-**1** has been adopted by other groups in a range of applications.⁶




Figure 1. Selection of chiral diamines.

Of course, diamine (+)-**1** is only a pseudo-enantiomer of (–)-sparteine and, as such, there will be differences in rates of reactions and enantioselectivity using (–)-sparteine and (+)-**1**. Notwithstanding the success of other pseudo-enantiomeric pairs of ligands (e.g., cinchona alkaloids), enantiomeric ligands are preferred in asymmetric synthesis. Hence, we searched for chiral diamines that would show comparable

[†] University of York.

[‡] Eli Lilly and Co. Ltd.

(1) Hoppe, D.; Hintze, F.; Tebben, P. *Angew. Chem., Int. Ed. Engl.* **1990**, *29*, 1422.

(2) Beak, P.; Kerrick, S. T.; Wu, S.; Chu, J. *J. Am. Chem. Soc.* **1994**, *116*, 3231.

(3) For a review, see: Hoppe, D.; Hense, T. *Angew. Chem., Int. Ed. Engl.* **1997**, *36*, 2282.


(4) Dearden, M. J.; Firkin, C. R.; Hermet, J.-P. R.; O'Brien, P. *J. Am. Chem. Soc.* **2002**, *124*, 11870.

(5) For a review, see: O'Brien, P. *Chem. Commun.* **2008**, 655.

enantioselectivity to (–)-sparteine in *s*-BuLi-mediated deprotonation reactions.

We were attracted to cyclohexane-derived diamines (e.g., TMCD), which are readily available in both enantiomeric forms. In particular, recent work from the Alexakis group has advocated the use of diamines such as (*R,R*)-**2–4** that, by way of differently functionalized amino groups, possess stereogenic nitrogen atoms upon complexation to organolithium reagents.^{7,8} Hence, we evaluated some asymmetric deprotonation reactions with *s*-BuLi/diamines (*R,R*)-**2–4**, and herein it is reported that diamine **4** is as effective as (–)-sparteine for the deprotonation of *N*-Boc pyrrolidine. We also describe an efficient multigram scale preparation of diamine (*R,R*)-**4** (and (*S,S*)-**4**) and two synthetic applications of diamine (*S,S*)-**4** where (+)-sparteine-derived stereochemistry is needed to obtain the appropriate enantiomer of the product.


Diamines (*R,R*)-**2–4** were prepared using routes that involved minor changes to those originally described by Alexakis⁷ (see Supporting Information). As a representative example, the synthesis of (*R,R*)-**4** is summarized in Scheme 1.



using L- and D-tartaric acid to give both salts (*R,R*)-**5** and (*S,S*)-**5**.⁹ Then, reaction of (*R,R*)-**5** with NaOH(aq)/MeO₂CCl gave a *bis*-methyl carbamate, which was reduced using LiAlH₄¹⁰ to deliver diamine (*R,R*)-**6**. Next, acylation of diamine (*R,R*)-**6** using *t*-butylacetyl chloride delivered a crude *bis*-amide that was reduced using LiAlH₄ to give diamine (*R,R*)-**4** in 72% yield after purification by Kugelrohr distillation over 4 steps (Scheme 1). The synthesis was readily achieved on a multigram scale: 10.0 g of salt (*R,R*)-**5**

produced 8.4 g of diamine (*R,R*)-**4** after distillation, the only purification required in the sequence.

With diamines (*R,R*)-**2–4** in hand, we evaluated them in different asymmetric deprotonation reactions. First, Beak's lithiation-trapping of *N*-Boc pyrrolidine **7** (\rightarrow **8**) was used to compare the three ligands. The results are shown in Scheme 2, together with those obtained with (–)-sparteine,



(+)-**1**,⁴ and (*R,R*)-TMCD.¹¹ The sterically hindered diamines (*R,R*)-**2** and (*R,R*)-**3** produced *s*-BuLi complexes that were unreactive (low yields with significant amounts of recovered starting material) and gave racemic adduct **8**. In contrast, moving the sterically hindered *t*-Bu group in the ligand one atom further along the *N*-alkyl chain relative to (*R,R*)-**3** gave a *s*-BuLi complex that delivered (*S*)-**8** of 95:5 er in 72% yield. The difference between diamines (*R,R*)-**3** and (*R,R*)-**4** is remarkable. Indeed, this is the first example of a non-sparteine-like diamine whose *s*-BuLi complex shows such high enantioselectivity.

Having established that diamine **4** was the optimal cyclohexane-derived ligand, asymmetric deprotonation of an *O*-alkyl carbamate,^{1,12} an epoxide,¹³ and a phosphine borane¹⁴ were investigated using *s*-BuLi/diamine **4** (Scheme 3). A satisfactory result was obtained with the *O*-alkyl carbamate: deprotonation of **9**, trapping with CO₂, and reduction with BH₃ gave alcohol (*S*)-**10** of 84:16 er (84% yield). This is slightly worse than a previous result using *s*-BuLi/TMCD on a sterically hindered *O*-alkyl carbamate.¹² In contrast, the enantioselectivity with cyclooctene oxide **11** and phosphine borane **13** were significantly worse than those obtained with (–)-sparteine. Apparently, the *s*-BuLi/diamine **4** complex

(6) (a) Johansson, M. J.; Schwartz, M.; Amedjkouh, M.; Kann, N. *Tetrahedron: Asymmetry* **2004**, *15*, 3531. (b) Morita, Y.; Tokuyama, H.; Fukuyama, T. *Org. Lett.* **2005**, *7*, 4337. (c) Wilkinson, J. A.; Rossington, S. B.; Ducki, S.; Leonard, J.; Hussain, N. *Tetrahedron* **2006**, *62*, 1833. (d) Stymiest, J. L.; Dutheil, G.; Mahmood, A.; Aggarwal, V. K. *Angew. Chem., Int. Ed.* **2007**, *46*, 7491.

(7) (a) Kizirian, J.-C.; Caille, J.-C.; Alexakis, A. *Tetrahedron. Lett.* **2003**, *44*, 8893. (b) Kizirian, J.-C.; Cabello, N.; Pinchard, L.; Caille, J.-C.; Alexakis, A. *Tetrahedron* **2005**, *61*, 8939. (c) Cabello, N.; Kizirian, J.-C.; Gille, S.; Alexakis, A.; Bernardinelli, G.; Pinchard, L.; Caille, J.-C. *Eur. J. Org. Chem.* **2005**, 4835. (d) Gille, S.; Cabello, N.; Kizirian, J.-C.; Alexakis, A. *Tetrahedron: Asymmetry* **2006**, *17*, 1045. (e) Perron, Q.; Alexakis, A. *Tetrahedron: Asymmetry* **2007**, *18*, 2503.

(8) Hoffmann, R. W.; Klute, W.; Dress, R. K.; Wenzel, A. *J. Chem. Soc., Perkin Trans. 2* **1995**, 1721.

(9) Larrow, J. F.; Jacobsen, E. N. *Org. Synth.* **1997**, *75*, 1.

(10) A long reaction time (48 h) for the LiAlH₄ reduction ensured that crude diamine (*R,R*)-**6** was of sufficient purity for subsequent reaction.


(11) Gallagher, D. J.; Beak, P. *J. Org. Chem.* **1995**, *60*, 7092.

(12) Würthwein, E.-U.; Behrens, K.; Hoppe, D. *Chem.-Eur. J.* **1999**, *5*, 3459.

(13) Hodgson, D. M.; Cameron, I. D.; Christlieb, M.; Green, R.; Lee, G. P.; Robinson, L. A. *J. Chem. Soc., Perkin Trans. 1* **2001**, 2161.

(14) Muci, A. R.; Campos, K. R.; Evans, D. A. *J. Am. Chem. Soc.* **1995**, *117*, 9075.


Scheme 3



does not show as broad a range of applicability as *s*-BuLi/(–)-sparteine or (+)-**1** although we have recently shown that the *s*-BuLi/diamine **4** complex gives high enantioselectivity in the lithiation-trapping of *N*-Boc piperidine.¹⁵

Our attention then focused on using *s*-BuLi/diamine **4**-mediated deprotonation of *N*-Boc pyrrolidine **7** in synthesis. In particular, to showcase diamine (*S,S*)-**4** as a useful (+)-sparteine surrogate, we used it in two syntheses where the stereochemistry required is opposite to that engendered by (–)-sparteine. Over the last 20 years, there has been considerable interest in the synthesis of indolizidine alkaloids from the *Dendrobates* family of neotropical frogs. We chose indolizidine 167B¹⁶ as a target and optimized a five-step synthesis (Scheme 4).

Scheme 4




Thus, *N*-Boc pyrrolidine **7** was deprotonated using *s*-BuLi/diamine (*S,S*)-**4** and allylated (via transmetalation to Cu)

using a protocol developed by Dieter.¹⁷ In this way, allylated pyrrolidine **15** of 85:15 er was produced (78% yield). A slightly reduced enantioselectivity is often encountered during these types of transmetalation-allylation procedures.¹⁷ Next, it was necessary to swap the *N*-protecting group to Cbz,¹⁸ which proceeded uneventfully to give *N*-Cbz protected **16** in 99% yield. Then, cross metathesis of **16** with allylic alcohol **17** gave **18** in 78% yield, which was oxidized with Dess-Martin periodinane to give enone **19** (72% yield), a known intermediate in Lhommet's,^{16c} Remuson's,^{16d} and Kim's^{16e} syntheses. Finally, treatment of enone **19** with H₂ and Pd/C gave indolizidine (–)-167B in 81% yield. This is one of the shortest and most efficient syntheses of indolizidine (–)-167B to date (5 steps, 35% overall yield), although the natural product was produced in a presumed 85:15 er.¹⁹

Diamine (*S,S*)-**4** was also utilized in a new strategy for the synthesis of *cis*-2,5-disubstituted pyrrolidines via two sequential lithiation-electrophilic trappings (Scheme 5). Thus,

Scheme 5



cis relative stereochemistry would be achieved using (–)-sparteine to introduce the E¹ substituent and then a (+)-sparteine equivalent (e.g., diamine (*S,S*)-**4**) to attach the E² group.²⁰ In contrast, use of (–)-sparteine in both steps would produce a *trans*-2,5-disubstituted pyrrolidine, as has been previously reported.²

This *cis*-pyrrolidine strategy was used to prepare pyrrolidine *cis*-**22** (Scheme 6), which is a key intermediate in the synthesis of the CCK antagonist (+)-RP 66803.²¹ To start with, *s*-BuLi/(–)-sparteine-mediated lithiation-Negishi coupling of *N*-Boc pyrrolidine **7** was used to prepare arylated adduct **20** (81% yield, 95:5 er), according to a protocol recently reported by Campos and co-workers.²² Then, the second lithiation was carried out using *s*-BuLi/diamine

(17) Dieter, K. R.; Oba, G.; Chandupatla, K. R.; Topping, C. M.; Lu, K.; Watson, R. T. *J. Org. Chem.* **2004**, *69*, 3076.

(18) The *N*-Boc analogue of **19** was successfully prepared but Boc deprotection and reaction with H₂ and Pd/C gave low yields of impure indolizidine (–)-167B.

(19) Our sample of indolizidine (–)-167B showed [α]_D²⁴ –89.5 (c 0.2 in CH₂Cl₂) (lit. (ref 16c) [α]_D²⁴ –115 (c 1.17 in CH₂Cl₂) for (–)-indolizidine 167B of ≥ 99:1 er), which is consistent with 85:15 er.


(20) For an isolated example of the synthesis of a *cis*-2,5-pyrrolidine via a *s*-BuLi/(–)-sparteine-mediated deprotonation, see: Wu, S.; Lee, S.; Beak, P. *J. Am. Chem. Soc.* **1996**, *118*, 715.

(21) For previous syntheses, see: (a) Manfré, F.; Pulicanai, J. P. *Tetrahedron: Asymmetry* **1994**, *5*, 235. (b) Haddad, M.; Imogai, H.; Larchevêque, M. *J. Org. Chem.* **1998**, *63*, 5680. (c) Davis, F. A.; Fang, T.; Goswami, R. *Org. Lett.* **2002**, *4*, 1599. (d) Severino, E. A.; Costenaro, E. R.; Garcia, A. L. L.; Correia, C. R. D. *Org. Lett.* **2003**, *5*, 305. (e) Rudolph, A. C.; Machauer, R.; Martin, S. F. *Tetrahedron Lett.* **2004**, *45*, 4895. (f) van Esseveldt, B. C. J.; Vervoort, P. W. H.; van Delft, F. L.; Rutjes, F. P. J. T. *J. Org. Chem.* **2005**, *70*, 1791.

(15) Coldham, I.; O'Brien, P.; Patel, J. J.; Raimbault, S.; Sanderson, A. J.; Stead, D.; Whittaker, D. T. E. *Tetrahedron: Asymmetry* **2007**, *18*, 2113.

(16) For previous syntheses, see: (a) Polniaszek, R. P.; Belmont, S. E. *J. Org. Chem.* **1990**, *55*, 4688. (b) Jefford, C. W.; Tang, Q.; Zaslona, A. J. *Am. Chem. Soc.* **1991**, *113*, 3513. (c) Fleurant, A.; Cèlerier, J. P.; Lhommet, G. *Tetrahedron: Asymmetry* **1992**, *3*, 695. (d) Peroche, S.; Remuson, R.; Gelas-Mialhe, Y.; Gramain, J.-C. *Tetrahedron Lett.* **2001**, *42*, 4617. (e) Kim, G.; Lee, E. *Tetrahedron: Asymmetry* **2001**, *12*, 2073. (f) Corvo, M. C.; Pereira, M. M. C. *Tetrahedron Lett.* **2002**, *43*, 455. (g) Amat, M.; Lior, N.; Hidalgo, J.; Escolano, C.; Bosch, J. *J. Org. Chem.* **2003**, *68*, 1919. (h) Reddy, P. G.; Baskaran, S. *J. Org. Chem.* **2004**, *69*, 3093. (i) Sun, Z.; Shouyun, Y.; Ding, Z.; Ma, D. *J. Am. Chem. Soc.* **2007**, *129*, 9300.

Scheme 6



(*S,S*)-**4** and subsequent trapping with CO_2 afforded acid *cis*-**21** which was not isolated. Instead, the crude carboxylic acid was converted into its methyl ester (using $\text{Me}_3\text{SiCHN}_2$) and Boc-deprotected to give pyrrolidine *cis*-**22**^{21b} (>99:1 er) in 33% isolated yield (after column chromatography). The reagent-controlled *cis*-stereoselectivity was essentially complete as <5% of pyrrolidine *trans*-**24** was produced (as judged by ^1H NMR spectroscopy of the crude product and comparison with a sample of *trans*-**24** prepared independently, *vide infra*). The efficiency of forming *cis*-**22** was compromised by competitive benzylic deprotonation of **20**,²³ which led to 22% of pyrrolidine **23**.²⁴ Nonetheless, our two-operation route to pyrrolidine *cis*-**24** from *N*-Boc pyrrolidine

7 is the shortest synthesis reported to date. Interestingly, *cis*-**22** was generated in >99:1 er, which is higher than the 95:5 er of the starting material **20**. Thus, the minor enantiomer of **20** is either not deprotonated by the chiral base or undergoes benzylic lithiation to ultimately give **23**. To demonstrate unequivocally the success of our *cis*-pyrrolidine strategy, lithiation-carboxylation of **20** using *s*-BuLi/(–)-sparteine and subsequent ester formation and Boc deprotection gave pyrrolidine *trans*-**24**^{21c} (27% yield) and optically active pyrrolidine **23** (18% yield, $[\alpha]_D -44.5$ (*c* 0.05 in CHCl_3)).

In summary, we have shown that diamine (*S,S*)-**4** is an efficient (+)-sparteine surrogate for the asymmetric deprotonation of *N*-Boc pyrrolidine **7**. It is easy to synthesize multigram quantities of diamine (*S,S*)-**4** and we have exemplified the usefulness of diamine (*S,S*)-**4** with concise syntheses of indolizidine (–)-**167B** and pyrrolidine *cis*-**22**. In addition, a convenient strategy for the synthesis of *cis*-2,5-disubstituted pyrrolidines has been disclosed.

Acknowledgment. We thank the BBSRC and Eli Lilly and Co. Ltd for a CASE award (to D.S.).

Supporting Information Available: Full experimental procedures and characterization data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL800109S

(22) Campos, K. R.; Klapars, A.; Waldman, J. H.; Dormer, P. G.; Chen, C.-Y. *J. Am. Chem. Soc.* **2006**, *128*, 3538.

(23) Xiao, D.; Lavey, B. J.; Palani, A.; Wang, C.; Aslanian, R. G.; Kozlowski, J. A.; Shih, N.-Y.; McPhail, A. T.; Randolph, G. P.; Lachowicz, J. E.; Duffy, R. A. *Tetrahedron Lett.* **2005**, *46*, 7653.

(24) Pyrrolidine **23** formed from this reaction was optically active $\{[\alpha]_D -7.1$ (*c* 0.9 in CHCl_3)} but we have so far been unable to determine its er or its absolute stereochemistry.